James R. Berenson, MD, Inc.

Tag Archives: accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma

A Phase 2 Study of Accelerated Elotuzumab Infusion, over Less than 1 Hour, in Combination with Lenalidomide and Dexamethasone, in Patients with Multiple Myeloma

March 5, 2017

Abstract

Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous

… Article

Multiple myeloma (active) is the most common type plasma cell cancer. However, the following are other forms of myeloma or myeloma-related conditions:

Monoclonal gammopathy of undetermined significance (MGUS)
Asymptomatic (smoldering/indolent) myeloma
solitary plasmacytoma of the bone
Extramedullary plasmacytoma
Light chain myeloma
Non-secretory myeloma
Osteosclerotic myeloma (POEMS syndrome)
Waldenstrom macroglobulinemia
Light chain amyloidosis
Plasma cell leukemia

Tag Archives: accelerated; elotuzumab; infusion rate; monoclonal antibody; multiple myeloma

A Phase 2 Study of Accelerated Elotuzumab Infusion, over Less than 1 Hour, in Combination with Lenalidomide and Dexamethasone, in Patients with Multiple Myeloma

Abstract

James R. Berenson, MD

Links

Subscribe

Contact Us